

Product Datasheet

NEO-811

Catalog No. **BP-02285** · CAS **3084635-77-5** · Form **free base** · Physical state **solid** · Color **White to off-white** · Version **1.0** · Revision **2026-09-07**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target Molecular Glues; HIF/HIF Prolyl-Hydroxylase	Research area Cancer
--	--------------------------------

Molecular formula **C₃₀H₃₀N₅O₄**

Molecular weight **543.5887**

STRUCTURE



DESCRIPTION

NEO-811 is a selective and orally active ARNT (HIF-1 β) molecular glue degrader. NEO-811 is mediated by CRL4-CRBN E3 ligase for ARNT degradation. NEO-811 can be used for the study of clear cell renal cell carcinoma (ccRCC) .

BIOLOGICAL ACTIVITY

In Vitro

NEO-811 is highly selective and does not degrade well-known neosubstrates. Transcriptomic profiling of NEO-811 activity across several VHL-deficient ccRCC cell lines confirmed suppression of HIF-2 α target genes, including cyclin D and vascular endothelial growth factor (VEGF). NEO-811 also uniquely suppresses expression of target genes regulated by other Class I bHLH-PAS transcription factors, including HIF-1 α and aryl hydrocarbon receptor (AHR). NEO-811 retains activity in HIF-2 α inhibitor-resistant cells that harbored previously described mutations

SOLUBILITY

soluble in DMSO

REFERENCES

- [1]. Jennifer Griffin, et al. Abstract 6734: Discovery and optimization of NEO-811, a first-in-class molecular glue degrader of ARNT, utilizing structure-based drug design. Cancer Res (2026) 86 (7_Supplement): 6734.
- [2]. J. Scott Lee, et al. Abstract 5791: Preclinical characterization of NEO-811, a novel molecular glue degrader of ARNT for the treatment of clear cell renal cell carcinoma. Cancer Res (2026) 86 (7_Supplement): 5791.